Development of SARS vaccines and therapeutics is still needed

Shibo Jiang^{1 2 3}, Lu Lu^{1 1}, Lanying Du^{2 2}

Affiliations

¹ Key Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China.
² The Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USA.
³ Key Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. shibojiang@fudan.edu.cn.

PMID:32201503
PMCID: PMC7079997
DOI: 10.2217/fvl.12.126

Editorial

Development of SARS vaccines and therapeutics is still needed

Shibo Jiang et al. Future Virol.2013 Jan.

.2013 Jan;8(1):1-2.

doi: 10.2217/fvl.12.126. Epub 2012 Dec 20.

Authors

Shibo Jiang^{1 2 3}, Lu Lu^{1 1}, Lanying Du^{2 2}

Affiliations

¹ Key Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China.
² The Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USA.
³ Key Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. shibojiang@fudan.edu.cn.

PMID:32201503
PMCID: PMC7079997
DOI: 10.2217/fvl.12.126

No abstract available

Keywords: HCoV-EMC; SARS; SARS-CoV; human coronavirus; receptor-binding domain; spike protein; therapeutics; vaccines.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References

1. Zaki AM, van Boheemen S, Bestebroer TM et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19) 1814–1820 (2012). - PubMed
1. Anderson LJ, Baric RS. Emerging human coronaviruses: disease potential and preparedness. N. Engl. J. Med. 367(19) 1850–1852 (2012). - PubMed
1. Butler D. SARS veterans tackle coronavirus. Nature 490(7418) 20 (2012). - PubMed
1. Zhong NS, Zheng BJ, Li YM et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 362(9393) 1353–1358 (2003). - PMC - PubMed
1. Peiris JSM, Lai ST, Poon LLM et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361(9366) 1319–1325 (2003). - PMC - PubMed

Website

1. WHO. Global Alert and Response.www.who.int/csr/don/2012_09_23/en/index.html

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Development of SARS vaccines and therapeutics is still needed

Affiliations

Development of SARS vaccines and therapeutics is still needed

Authors

Affiliations

Conflict of interest statement

References

Website

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous